Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis

Mo, Jingxin; Wang, Li; Huang, Xiaojia; Lu, Bing; Zou, Changye; Wei, Lili; Chu, Jianping; Eggers, Paul K.; Chen, Shen; Raston, Colin L.; Wu, Jun; Lim, Lee Yong; Zhao, Wei

doi:10.1039/c7nr04473a

Cited by 43 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cervical carcinoma xenograft was produced by injecting HeLa cells (5×10 6 cells in 200 µL of PBS) cells subcutaneously into the right armpit of BALB/c nude mice, which was grouped randomly (7 groups). 31 FA-CBP/PTX-LPNs (contained 5 mg/kg CBP and 5 mg/kg PTX), FA-CBP-LPNs (contained 10 mg/kg CBP), FA-PTX-LPNs (contained 10 mg/kg PTX), CBP/PTX-LPNs (contained 5 mg/kg CBP and 5 mg/kg PTX), free CBP/PTX (contained 10 mg/kg CBP and 10 mg/kg PTX), FA-LPNs, and 0.9% saline were administered intravenously once every three days. The tumors and animal weights were measured.…”

Section: In Vivo Tissue Distribution and Anticancer Ability Of Lpnsmentioning

confidence: 99%

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

Wang¹

2020

DDDT

View full text Add to dashboard Cite

Purpose: Cervical cancer is one of the most common causes of death among women globally. Combinations of cisplatin, paclitaxel, bevacizumab, carboplatin, topotecan, and gemcitabine are recommended as first-line therapies. Methods: This study focuses on the development of folate-decorated, pH-sensitive lipidpolymer hybrid nanoparticles (LPNs). Loading carboplatin (CBP) and paclitaxel (PTX), LPNs were expected to combine the therapeutic effects of CBP and PTX, thus show synergistic ability on cervical cancer. Results: FA-CBP/PTX-LPNs showed the sizes of 169.9 ± 5.6 nm, with a narrow size distribution of 0.151 ± 0.023. FA-CBP/PTX-LPNs exhibited pH-responsive drug release, high cellular uptake efficiency (66.7 ± 3.1%), and prominent cell inhibition capacity (23 ± 1.1%). In vivo tumor distribution and tumor inhibition efficiency of FA-CBP/PTX-LPNs was the highest, with no obvious body weight lost. Conclusion: High tumor distribution and remarkable antitumor efficiency obtained using in vitro as well as in vivo models further proved the FA-CBP/PTX-LPNs is a promising tool for cervical cancer therapy.

show abstract

Section: In Vivo Tissue Distribution and Anticancer Ability Of Lpnsmentioning

confidence: 99%

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

Wang¹

2020

DDDT

View full text Add to dashboard Cite

show abstract

“…Mo et al [105] designed a novel folic acid-PEG-conjugated p-phosphonated calix [4]arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5:1, mol : mol) to utilise their potential synergistic effect against OC cells. The Fp-PCNs loaded with PAC and CAR (Fp-PCNPAC þ CAR) resulted in a remarkable efficacy in the suppression of OC, both in vitro and in vivo.…”

Section: Skov-3 Female Balb/c Mice 88mentioning

confidence: 99%

RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted

Gupta

Pathak

Gupta

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Ovarian cancer is the second most common gynaecological malignancy. It usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with poor diagnosis. Despite the chemosensitivity of intraperitoneal chemotherapy, the majority of patients is relapsed and eventually dies. In addition to the challenge of early detection, its treatment presents several challenges like the route of administration, resistance to therapy with recurrence and specific targeting of cancer to reduce cytotoxicity and side effects. In ovarian cancer therapy, nanocarriers help overcome problems of poor aqueous solubility of chemotherapeutic drugs and enhance their delivery to the tumour sites either by passive or active targeting, and thus reducing adverse side effects to the healthy tissues. Moreover, the bioavailability to the tumour site is increased by the enhanced permeability and retention (EPR) mechanism. The present review aims to describe the current conventional treatment with special reference to passively and actively targeted drug delivery systems (DDSs) towards specific receptors designed against ovarian cancer to overcome the drawbacks of conventional delivery. Conclusively, targeted nanocarriers would optimise the intra-tumour distribution, followed by drug delivery into the intracellular compartment. These features may contribute to greater therapeutic effect. ARTICLE HISTORY

show abstract

“…GSC spheres of U87 cells were formed and maintained in suspension in serum-free DMEM/F12 supplemented with N2, G5 and B27, plus 1% penicillin/streptomycin (ThermoFisher Scientific). [21] Culture supernatants were collected 2 days later and processed for exosome purification by ultracentrifugation steps. [22]…”

Section: Cell Culturementioning

confidence: 99%

Zinc Sulfide-Based Hybrid Exosome-Coated Nanoplatform for Targeted Treatment of Glioblastoma in an Orthotopic Mouse Glioblastoma Model

Tang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

To eliminate glioblastoma stem-like cells, fine core-shell nanoparticles, consisting of hollow ZnS nanoparticles covered by hybrid exosome shell containing exosome and dual responsive iRGD derived phosphatidylserine, and incorporated with autophagic inhibitor hydroxychloroquine (HCQ), denoted as HCQ@ZnS@exo@iRGD were synthesized, characterized and evaluated in vitro and in vivo. The highest release performance of HCQ from HCQ@ZnS@exo@iRGD was attained under low pH and high glutathione conditions. Hybrid exosomes enabled the glioblastoma stem-like cells (GSCs) targeting properties along with excellent permeated ability across BBB were observed both in 3D cells spheroids and in orthotopic mouse glioblastoma model. Visible light source is used to trigger the ROS induction of hollow ZnS nanopartilces. Meanwhile ZnS could produce H2S gas and release its cargo of HCQ as well in situ. Consequently, significant targeted damage to GSCs is achieved due to the combined cytotoxic effects and autophagy-deactivation enabled by HCQ@ZnS@exo@iRGD nanocomposites, indicating its considerable potential for effective GBM treatment.

show abstract

Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis

Cited by 43 publications

References 22 publications

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted

Zinc Sulfide-Based Hybrid Exosome-Coated Nanoplatform for Targeted Treatment of Glioblastoma in an Orthotopic Mouse Glioblastoma Model

Contact Info

Product

Resources

About